Company Profile

Halolife was established in 2019. Its predecessor was (Xiamen Halosyntech Co., Ltd., which was established in 2012. Located in Xiamen Biopharmaceutical Pilot Plant, it is a high-tech enterprise integrating R&D, production, sales and import and export of pharmaceutical raw materials and advanced pharmaceutical intermediates.
Halolife has successfully developed more than a dozen of the latest drugs in the fields of anti-virus, anti-tumor and antibacterial. Our products have won the favor of customers in more than 20 countries including Europe, America, Asia and Africa. At present, the company has established a professional research team led by a senior overseas returnee Ph.D., with first-class synthesis, analysis and preparation laboratories, a complete pilot plant and production plant, which can efficiently provide active pharmaceutical ingredients (API) and One-stop service for intermediates from small molecule screening, process optimization, and commercial production.